{"id":"metformin-discontinue","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity. The entry 'Metformin discontinue' appears to refer to a clinical decision or study protocol involving cessation of metformin treatment, not a novel pharmaceutical agent. This is not a drug development program but rather a therapeutic intervention.","oneSentence":"This entry represents a discontinuation of metformin therapy rather than a new drug entity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:54:33.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02437656","phase":"PHASE2","title":"Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-05","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT07372625","phase":"PHASE1","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2026-02-04","conditions":"TP53 Y220C Mutation, Advanced Solid Tumors","enrollment":14},{"nctId":"NCT07441187","phase":"","title":"Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-20","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":300},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT06605703","phase":"PHASE4","title":"A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"WW International Inc","startDate":"2024-09-18","conditions":"Obesity, Overweight","enrollment":226},{"nctId":"NCT02087826","phase":"NA","title":"Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Genetics, Metabolism, Type 2 Diabetes","enrollment":1017},{"nctId":"NCT06884683","phase":"PHASE2","title":"Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-09-17","conditions":"Metastatic Renal Cell Carcinoma","enrollment":12},{"nctId":"NCT06296836","phase":"PHASE4","title":"Effect of Continuing Versus Holding Metformin During Hospitalizations.","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-01-21","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT06781775","phase":"PHASE4","title":"GDM: Insulin with or Without Metformin?","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-12-12","conditions":"Gestational Diabetes","enrollment":130},{"nctId":"NCT06775093","phase":"NA","title":"Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":392},{"nctId":"NCT02515773","phase":"PHASE4","title":"Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs","status":"COMPLETED","sponsor":"Melissa Delbello","startDate":"2015-12","conditions":"Bipolar Disorder","enrollment":1565},{"nctId":"NCT00984490","phase":"NA","title":"Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2009-09","conditions":"Breast Cancer","enrollment":5},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT02420652","phase":"PHASE2","title":"Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-06-23","conditions":"Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":27},{"nctId":"NCT04089280","phase":"NA","title":"Probiotics in Metformin Intolerant Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2018-10-16","conditions":"Diabetes Mellitus, Type 2, Metformin Adverse Reaction","enrollment":37},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT04692415","phase":"PHASE4","title":"Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2018-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT04502303","phase":"PHASE2","title":"18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT04412746","phase":"","title":"Covid-19 and Diabetes in West of Algeria","status":"UNKNOWN","sponsor":"Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen","startDate":"2020-04-01","conditions":"Coronavirus Infections, Diabetes Mellitus, Prevalence","enrollment":100},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01578551","phase":"PHASE2","title":"Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-05","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma","enrollment":25},{"nctId":"NCT02694289","phase":"NA","title":"Effects of Metformin in Heart Failure Patients","status":"WITHDRAWN","sponsor":"Maya Guglin","startDate":"2016-11","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT02866786","phase":"PHASE4","title":"The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS","status":"COMPLETED","sponsor":"S.C.B. Medical College and Hospital","startDate":"2016-08-15","conditions":"Polycystic Ovary Syndrome","enrollment":101},{"nctId":"NCT02393573","phase":"NA","title":"Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-11","conditions":"Pre-Diabetes, Major Lung or Abdominal Surgery, Insulin Resistance","enrollment":7},{"nctId":"NCT03236740","phase":"PHASE4","title":"OCP vs Metformin on Ovarian Stromal Blood Flow in PCOS","status":"COMPLETED","sponsor":"S.C.B. Medical College and Hospital","startDate":"2017-08-01","conditions":"PCOS","enrollment":101},{"nctId":"NCT02978547","phase":"PHASE2","title":"The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2019-01","conditions":"Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT03179254","phase":"PHASE4","title":"Type 2 Diabetes and Ambulatory Surgery Patients","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-03-22","conditions":"Diabetes Type 2","enrollment":160},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00909480","phase":"PHASE4","title":"Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":457},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT03030300","phase":"PHASE4","title":"Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2008-01","conditions":"Type2 Diabetes","enrollment":170},{"nctId":"NCT02138097","phase":"","title":"Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":615067},{"nctId":"NCT01099618","phase":"PHASE4","title":"Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment","status":"COMPLETED","sponsor":"Dawn Smiley MD","startDate":"2010-03","conditions":"Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia","enrollment":48},{"nctId":"NCT01278160","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT01873859","phase":"NA","title":"Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2013-05","conditions":"Diabetes Mellitus, Lactic Acidosis","enrollment":166},{"nctId":"NCT01573377","phase":"NA","title":"Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2012-02","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":40},{"nctId":"NCT00965549","phase":"PHASE4","title":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":463},{"nctId":"NCT01717911","phase":"PHASE4","title":"ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":160},{"nctId":"NCT00063232","phase":"PHASE2","title":"Treating Nonalcoholic Steatohepatitis (NASH) With Metformin","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-06","conditions":"Hepatitis","enrollment":28},{"nctId":"NCT01334684","phase":"NA","title":"Gene Expression Profiles and Metformin Efficacy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2011-05","conditions":"Type 2 Diabetes","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Metformin"],"phase":"marketed","status":"active","brandName":"Metformin discontinue","genericName":"Metformin discontinue","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}